Company intelligence
Elevar Therapeutics
Elevating Outcomes, Evolving Therapeutic Potential, Engaging with Purpose
About Elevar Therapeutics
Elevar Therapeutics is a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Our experience is rooted in oncology, and we apply the same rigor and diligence that comes with this knowledge to identifying and developing promising medicines for complex yet under-treated health conditions across a range of therapeutic areas. Elevating Outcomes: We take a relentless and inventive approach towards developing and advancing next-generation, best-in-class therapies that have the potential to set new standards of care and improve treatment experiences. Evolving Therapeutic Potential: We identify areas where we can develop, build upon or evolve medicines that offer patients improved clinical outcomes. Engaging With Purpose: We are committed to engaging with the highest ethical standards, driven by a passion to address the underserved needs of patients, caregivers, and healthcare providers.
Verified activity
Signals from Elevar Therapeutics
4 published signals
Operations & Supply
Elevar Therapeutics closed its offices today to allow the team to recharge.
Reported by Elevar Therapeutics
Presence & Recognition
Elevar Therapeutics recognizes the strength and resilience of children affected by cancer, families, caregivers, healthcare professionals, and researchers during Childhood Cancer Awareness Month.
Reported by Elevar Therapeutics
Presence & Recognition
Elevar Therapeutics published a press release on LinkedIn.
Reported by Elevar Therapeutics
Legal & Regulatory
Elevar Therapeutics is preparing for the FDA PDUFA target action date for lirafugratinib approaching on September 25, 2026.
Reported by Elevar Therapeutics